136058-75-8

Upstream product

• 1761-61-1 5-bromosalicyclaldehyde 

Downstream Products

• 132672-22-1 5-[2-(5-Methyl-2-m-tolyl-oxazol-4-ylmethyl)-benzofuran-5-ylmethyl]-oxazolidine-2,4-dione 
• 136058-85-0 2-(5-Methyl-2-m-tolyl-oxazol-4-ylmethyl)-benzofuran-5-carbonitrile 
• 136058-81-6 4-(5-Bromo-benzofuran-2-ylmethyl)-5-methyl-2-m-tolyl-oxazole 
• 132646-35-6 2-<<5-methyl-2-(3-methylphenyl)-4-oxazolyl>methyl>benzofuran-5-carboxaldehyde 
• 136058-78-1 (5-Bromo-benzofuran-2-yl)-(5-methyl-2-m-tolyl-oxazol-4-yl)-methanol 

Relevant academic research and scientific papers

Antihyperglycemic activity of new 1,2,4-oxadiazolidine-3,5-diones

A series of 1,2,4-oxadiazolidine-3,5-diones was synthesized and evaluated as oral antihyperglycemic agents in the obese insulin resistant db/db and ob/ob mouse - the two models for Type 2 diabetes mellitus. The majority of the prepared methoxy- and ethoxy-linked oxazole 1,2,4-oxadiazolidine-3,5-diones normalized plasma glucose levels at the 100 mg kg-1 oral dose in the db/db diabetic mouse model, and several amongst them reduced the glucose levels at the 20 mg kg-1 oral dose. The most potent compounds in the db/db mouse model were also active in the ob/ob mouse model normalizing the plasma glucose levels at the 20 mg kg-1 oral dose. The trifluoromethoxy analog 32 was the most active compound of the series, reducing significantly the plasma glucose levels at the 5 mg kg-1 oral dose. Oxadiazole-tailed 1,2,4-oxadiazolidine-3,5-diones were also active in both the db/db and ob/ob diabetic mouse models normalizing plasma glucose levels at the 100 mg kg-1 oral dose.

Benzyloxazolidine-2,4-diones as potent hypoglycemic agents

A series of benzyloxazolidine-2,4-diones, containing oxazole-based side chains, were found to lower blood glucose levels in the genetically obese ob/ob mouse. Incorporation of a benzofuran structural element in these compounds provides greatly enhanced in vivo potency. The syntheses and structure-activity relationships for this series are detailed.